Device Trials Require Unique Financial Conflict Of Interest Solution
This article was originally published in The Gray Sheet
Executive Summary
HHS should tailor its approach to disclosure of financial conflict of interest in device clinical trials vis avis pharmaceutical studies, AdvaMed (formally HIMA) Executive VP-Technology and Regulatory Affairs Jim Benson maintained.